Trigeminal Neuralgia Drug Pipeline Research Report 2023: Comprehensive Insights on 10 Companies and 10 Pipeline Drugs Featuring Biogen, Biohaven Pharmaceuticals, Noema Pharma, & Pfizer - ResearchAndMarkets.com

The "Trigeminal Neuralgia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

The "Trigeminal Neuralgia- Pipeline Insight, 2023" report offers comprehensive insights into the Trigeminal Neuralgia pipeline landscape, featuring information on more than 10 companies and over 10 pipeline drugs.

This comprehensive resource provides detailed profiles of pipeline drugs, covering both clinical and nonclinical stages. The report delves into therapeutics assessment based on product type, stage, route of administration, and molecule type. Additionally, it sheds light on inactive pipeline products within this domain.

Leading companies and academic institutions are dedicated to addressing challenges and exploring opportunities that can shape the future of Trigeminal Neuralgia research and development. The therapies currently in development focus on innovative approaches to enhance the treatment and management of Trigeminal Neuralgia.

This segment of the Trigeminal Neuralgia report presents an in-depth analysis of various drugs across different stages of clinical development, including phases III, II, I, preclinical, and Discovery. It facilitates a comprehensive understanding of clinical trial particulars, pharmacological actions, collaborative agreements, and the latest updates through news and press releases.

Trigeminal Neuralgia Emerging Drugs

Vixotrigine: Biogen

Vixotrigine (BIIB074) is a voltage and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule. Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy. It is being developed by Biogen for the treatment of Trigeminal Neuralgia and is in Phase III of development.

Rimegepant: Biohaven Pharmaceuticals

Rimegepant is a Phase II calcitonin gene-related peptide receptor antagonists. It is being developed by Biohaven pharmaceuticals. The trail got initiated in June 2019 and is expected to get completed by October 2022 with expected 30 enrolled participants. (NCT03941834).

Trigeminal Neuralgia: Therapeutic Assessment

This segment of the report provides insights about the different Trigeminal Neuralgia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Trigeminal Neuralgia

There are approx. 10+ key companies which are developing the therapies for Trigeminal Neuralgia. The companies which have their Trigeminal Neuralgia drug candidates in the most advanced stage, i.e. phase III include, Biogen.

Key Questions Answered

• How many companies are developing Trigeminal Neuralgia drugs?
• How many Trigeminal Neuralgia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Trigeminal Neuralgia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Trigeminal Neuralgia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Trigeminal Neuralgia and their status?
• What are the key designations that have been granted to the emerging drugs?

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Trigeminal Neuralgia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Players

• Biogen
• Biohaven Pharmaceuticals
• Noema Pharma AG
• Pfizer

Key Products

• Vixotrigine
• Rimegepant
• Basimglurant

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/qpjxu

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230912603505/en/